SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert Cohen who wrote (103)11/14/1996 1:42:00 AM
From: John Metcalf   of 2742
 
Greetings, Bob. Hal Smith's statement that there had been assignments is consistent with CIST's press release, which presumably was written by Mr. Smith. It could be construed simply to mean that Immunex assigned rights to Cistron, as indicated in the press release concerning the settlement. Remember that the lawsuit devolved from IMMX's patent filing which infringed CIST's prior patent. To twist the phrase of Sherlock Holmes, when subtlety and intrigue have been exhausted, consider the obvious.

I am not wary of the PR man. I've found no unsubstatiated nor overstated claims in any company document. You can't say that about every biotech company.

With regard to fighting insiders, the answer should be obvious to an old shaman like yourself. You simply relax and float downstream with them -:) If they're going to build the company, ride along with them. If they're not, fighting will not avail.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News